TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject has had an ICD previously implanted~* subject has drug-refractory monomorphic VT~* subject is a candidate for ischemic VT RF ablation~* subject has had a myocardial infarction~* subject has a LVEF less than or equal to 35%~Exclusion Criteria:~* subject has non-ischemic VT~* subject has a history of stroke within 1 month prior to enrollment~* subject has had an acute myocardial infarction within 30 days prior to enrollment~* subject has unstable angina~* subject has undergone cardiac surgery within 60 days prior to enrollment~* subject is pregnant or nursing~* subject has a limited life expectancy of 1 year or less (Subjects requiring LVAD/IABP intraprocedural support may be enrolled as long as life expectancy is at least 1 year following the ablation procedure.)~* subject is unable or unwilling to cooperate with study procedures~* subject has a known presence of intracardiac thrombi as determined by echocardiography~* subject has a major contraindication to anticoagulation therapy or coagulation disorder~* subject has had a previous pericarditis or cardiac tumor~* subject has had previous thoracic radiation therapy~* any other reason the investigator considers the subject ineligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Magnetic navigation (Type: EXPERIMENTAL): Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
- Manual navigation (Type: ACTIVE_COMPARATOR): Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The WALK-Copenhagen Trial (WALK-Cph): a Mixed Methods Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* +65 years~* acutely admitted to intervention wards~* able to walk independently with or without walking aid~Exclusion Criteria:~* in isolation~* inability to cooperate~* not able to speak or understand Danish~* in treatment for cancer~* terminally ill~* transferred to intensive care unit or another ward within 24 hours after admission

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): 1) On admission, patients will receive a welcome folder focusing on physical activity; 2) daily during hospitalization, patients will be encouraged to walk along a walk path in the hallway; 3) during hospitalization, patients will be encouraged to consult and use posters with exercises (sit to stand, heel raise, balance); 4) on admission, patients will receive a prescribed walk plan with 3 daily walking sessions to perform during hospitalization (3 times 1 minute, 5 minutes or 10 minutes); 5) during hospitalization patients will be motivated to pick up of clothes and beverages themselves; 6) patients will be discharged with a walk plan to use at home; 7) after discharge the municipality will follow up on patients receiving home care and patients with a rehabilitation plan
- Usual care (Type: NO_INTERVENTION): All patients admitted to the control wards will receive usual care during and after hospitalization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Simplus and Eson Non-Invasive Ventilation (NIV) Evaluation - Germany

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18+~* Existing full face mask user or a nasal mask user~* Prescribed NIV therapy for at least 3 months~Exclusion Criteria:~* Inability to give informed consent~* Pregnant or think they may be pregnant~* Anatomical or physiological conditions making NIVtherapy inappropriate~* Patients who are in a coma or decreased level of consciousness~* Existing Simplus and Eson users

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full face/Nasal masks (Type: EXPERIMENTAL): Simplus/Eson

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-85~* Native English speakers~* Neurological diagnosis of amnestic mild cognitive impairment (aMCI)~Exclusion Criteria:~* brain tumors~* skull defects~* epilepsy~* metal implants/devices above the neck~* eczema or sensitive skin~* insomnia~* sleep apnea that requires use of a CPAP machine~* rapid eye movement (REM)-sleep behavior disorder~* currently pregnant or trying to become pregnant during the study period~* diagnosis of cognitive impairment \*cognitive impairment required for MCI arms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Effects of tACS during SWS- Standard/Nested 1 (Type: ACTIVE_COMPARATOR): This is a triple cross-over with a sham control condition; the standard tACS administered first, then Nested, then sham.
- Effects of tACS during SWS- Older Adults Active 1 (Type: ACTIVE_COMPARATOR): This is a double cross-over with a sham control condition; the tACS administered first, then the sham
- Effects of tACS during SWS- MCI Active 1 (Type: ACTIVE_COMPARATOR): This is a cross-over with a sham control condition; the standard tACS administered first, then sham.
- Effects of tACS during SWS- Standard/Nested 2 (Type: ACTIVE_COMPARATOR): This is a triple cross-over with a sham control condition; the standard tACS administered first, then sham, then nested tACS.
- Effects of tACS during SWS- Standard/Nested 3 (Type: ACTIVE_COMPARATOR): This is a triple cross-over with a sham control condition; the sham tACS administered first, then nested tACS, then standard tACS.
- Effects of tACS during SWS- Older Adults Active 2 (Type: ACTIVE_COMPARATOR): This is a double cross-over with a sham control condition; the sham administered first, then the tACS.
- Effects of tACS during SWS- MCI Active 2 (Type: ACTIVE_COMPARATOR): This is a cross-over with a sham control condition; the sham administered first, then standard tACS.
- Effects of tACS during SWS- Standard/Nested 4 (Type: ACTIVE_COMPARATOR): This is a triple cross-over with a sham control condition; the sham tACS administered first, then standard tACS, then nested tACS.
- Effects of tACS during SWS- Standard/Nested 5 (Type: ACTIVE_COMPARATOR): This is a triple cross-over with a sham control condition; the nested tACS administered first, then sham, then standard tACS.
- Effects of tACS during SWS- Standard/Nested 6 (Type: ACTIVE_COMPARATOR): This is a triple cross-over with a sham control condition; the nested tACS administered first, then standard tACS, then sham.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Attentional Re-training for Chronic Pain Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic pain patients, i.e., chronic pain that has been ongoing for more than 3 months.~* Patient follow-up in the urology department of the University Hospital of Nantes~* Age between 18 and 65~* Good understanding of French, able to read and write.~* Serve correctly and painlessly with both hands~* Affiliated with a social security system~* Signed consent~* With internet access.~Exclusion Criteria:~* Current and unstable psychiatric (mood disorders, anxiety disorders) and addictive (substance use disorders, alcoholic or otherwise, excluding nicotine) disorders.~* Does not use both hands properly and painlessly~* Depression (BDI-II ≤18)~* Patient under guardianship, curatorship or judicial protection~* Pregnant or breastfeeding woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- G1 (Type: EXPERIMENTAL): None
- G2 (Type: EXPERIMENTAL): None
- G3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Premature infants with gestational age between \<32 weeks regardless of birth weight~Exclusion Criteria:~1. Inborn errors of metabolism~2. Need for exchange transfusion~3. Multiple congenital anomalies~4. Renal failure (defined as urine output \<1ml/k/h \>24h, creatinine \>1.8, or diagnosis of non-oliguric renal failure as determined by Pediatric nephrology)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gestational age < 32 weeks (Type: None): Premature infants with gestational age between \<32 weeks regardless of birth weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Registry on the HARPOON Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are clinically suitable for treatment with the HARPOON™ System, as per the Instructions for Use (IFU), will be evaluated for inclusion in the registry.~Exclusion Criteria:~* N/A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HARPOON™ MVRS (Type: OTHER): Subjects who were treated with the HARPOON MVRS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-valvular Atrial Fibrillation~* CHA2DS2-VASc Score \> or = to 2~* Never been treated with Apixaban (Eliquis) or prior treatment of \< 1 month~* Candidate for oral anticoagulation as assessed by a treating physician~Exclusion Criteria:~* Valvular Atrial Fibrillation (Rheumatic valve disease,Moderate or greater mitral stenosis,Mechanical cardiac valve)~* Active Bleeding~* Prior treatment with Apixaban \>1 month~* Recent stroke within 7 days~* Dementia~* Implanted devices not compatible with MRI/any cardiac implanted device~* Claustrophobia~* Active alcohol/drug abuse~* Life expectancy \< 1 year~* Taking asprin with \>100mg doses~* Known hypersensitivity to warfarin or Apixaban~* Severe renal insufficiency~* Prior severe bleeding (Intracranial bleeding (subdural, subarachnoid, intraparenchymal bleeding),GI bleed requiring transfusion,Bleeding from other sites requiring transfusion)~* Psychosocial reasons that make study participation impractical~* Currently enrolled in another IND or IDE trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints~* Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or that could impact the scientific integrity of the study.~* Prisoners or subjects who are involuntarily incarcerated~* Subjects who are compulsorily detained for treatment of either psychiatric or physical illness~* Current or expected systemic treatment with strong dual inhibitors of CYP3A4 and P-gp (Any one of rifampin, carbamazepine, phenytoin, St. John's Wort, ketoconazole, itraconazole, ritonavir, clarithromycin)~* Need for dual anti-platelet therapy with aspirin and another agent such as thienopyridine

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eliquis (Type: ACTIVE_COMPARATOR): None
- Warfarin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Direct Current Stimulation for Depression in Alzheimer's Disease Patient - Preliminary Research

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who meets criteria of probable Alzheimer's disease defined by NINCDS-ADRDA research criteria.~2. Participants who meets criteria of depression in Alzheimers defined by NIMH criteria.~3. Participants who have been on fixed dose (including participants without any prescription) of antidepressants for at least two weeks on the screening visit.~4. Participants who have been on fixed dose (including participants not prescribed) of antidementia drugs (donepezil, rivastigmine, galantamine, and memantine) for at least for weeks on the screening visit.~5. Ambulatory participants with or without any aiding device~6. Participants who have one caregiver, who must live with the patient at least ten hours a week and must report the patient's behavior.~7. A study partner who can report how the participant is doing is needed.~8. Eligible family member must sign and give consent on behalf of participants, whereas participants can give assent.~Exclusion Criteria: Following potential participants will be excluded~1. In case their cognitive deficits are better explained by another disease (e.g., cerebral infarction, Parkinson disease, multiple sclerosis, normotensive hydrocephalus).~2. In case they have history of epilepsy~3. In case they need treatment by antipsychotics due to significant psychotic symptoms~4. In case they have urgent risk of suicide or severe depression and any doctor require their hospitalization to psychiatric units.~5. In case they have history of ineffectiveness with electroconvulsive therapy (ECT) or transcranial direct current stimulation (tDCS)~6. In case ECT or tDCS is clinically contraindicated~7. In case they are taking benzodiazepines or antiepileptic drugs on the screening visit~8. In case they scored less than ten on Mini Mental State Exam (MMSE) or scored 3 or more on Clinical Dementia Rating (CDR)~9. In case his/her GDS score is lower than 6 at baseline~10. In case he/she is unable to agree video recording on evaluation interview

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Active stimulation (Type: ACTIVE_COMPARATOR): Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
- Sham stimulation (Type: SHAM_COMPARATOR): Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically confirmed diagnosis of NSCLC with PD-L1 expression of ≥1% based on FDA-approved test~* No prior treatment with checkpoint inhibitors or more than one regimen of chemotherapy including epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation directed therapy for advanced or metastatic disease~* Disease must have at least 1 measurable target lesion by RECIST 1.1~* Adequate major organ functions as evidenced by laboratory findings within 14 days prior to first dose~* Eastern Cooperative Oncology Group (ECOG) ≤2 and must have a life expectancy of ≥12 weeks~Exclusion Criteria:~* History of grade ≥3 hypersensitivity reactions to monoclonal antibodies~* Participation in another interventional clinical trial within 28 days or less than 5 half-lives of investigational agent before the first dose~* Recurrent pleural effusion requiring repetitive palliative thoracentesis within 3 months prior to study entry (except patients with a PleurX™ port)~* Active, known or suspected autoimmune disease or history of immune-mediated toxicity leading to discontinuation of previous checkpoint inhibitor treatment should be administered in (neo)adjuvant setting. Exceptions are for type I diabetes mellitus, hyperthyroidism requiring hormone-replacement or skin only disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic therapy~* Active pneumonitis, history of non-infectious pneumonitis that required treatment with steroids, or history of interstitial lung disease~* Received approved live vaccines within 30 days of planned first dose. Intranasal influenza vaccines (e.g. Flu-Mist) are not allowed, however inactivated viral vaccines or vaccines based on subviral component are allowed~* Any condition requiring chronic systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications. And any steroids use within 14 days of first dose except for inhaled or topical steroids.~Note: Other protocol-defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HBI-8000 in combination with pembrolizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient with a hematologic or oncologic diagnosis without morphological evidence of disease in which allogeneic HSCT is thought to be beneficial.~2. Patients must have a related donor who is a two or more allele mismatch at the HLA-A; B; C; DR loci.~3. Patients must have adequate organ function:~   1. LVEF (Left ventricular ejection fraction) of \>50%~  2. Diffusion Capacity for Carbon Monoxide (DLCO) \>50% of predicted corrected for hemoglobin~  3. Adequate liver function as defined by a serum bilirubin \<1.8, Aspartate Aminotransferase (AST) or alanine aminotransferase (ALT) \< 2.5X upper limit of normal~  4. Creatinine clearance of \> 60 ml/min~4. Performance status \> 80% (TJU Karnofsky)~5. Hematopoietic Comorbidity Index (HCT-CI) Score \< 5 Points~6. Patients must be willing to use contraception if they have childbearing potential~7. Able to give informed consent, or if decisionally impaired, have a legal next of kin or guardian that can give informed consent~Exclusion Criteria:~1. Performance status \< 80 % (TJU Karnofsky)~2. HCT-CI Score \> 5 Points~3. Combination of Performance status of \< 80% (TJU Karnofsky) and an HCT-CI of 4 points or more.~4. HIV positive~5. Active involvement of the central nervous system with malignancy~6. Psychiatric disorder that would preclude patients from signing an informed consent~7. Pregnancy~8. Patients with life expectancy of \< 6 months for reasons other than their underlying hematologic/oncologic disorder~9. Patients who have received alemtuzumab within 8 weeks of the transplant admission, or who have recently received horse or rabbit anti-thymocyte globulin and have an ATG level of \> 2 ugm/ml~10. Patients who cannot receive cyclophosphamide~11. Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (haploidentical allogeneic HSCT) (Type: EXPERIMENTAL): Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues